Blood test could guide pancreatic cancer therapy
NCT ID NCT04241367
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study looked at whether a simple blood test (liquid biopsy) can find genetic markers that predict how well pancreatic cancer treatments work. Researchers analyzed DNA from tumors circulating in the blood of 420 patients with pancreatic cancer. The goal was to discover biomarkers that could help personalize treatment in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors choose better treatments for pancreatic cancer patients based on their tumor's genetic markers.
- What could go wrong
- This is an observational study that does not test a new treatment, so it will not directly improve patient outcomes. The findings may not lead to immediate changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREAS ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NATIONAL CANCER CENTER 323, Ilsan-ro, Ilsandong-gu,
Goyang-si, Gyeonggi-do, 410-769, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple blood test catch pancreatic cancer before It's too late?
- Scientists hunt for clues to prevent a common complication after pancreatic cancer surgery
- New drug THE-0504 enters human testing for tough cancers
- Gut bacteria may forecast surgery risks in pancreatic cancer patients
- New antibody combo takes on Hard-to-Treat cancers
- Liquid biopsy study halted: did it help guide cancer care?